Award
National Center for Advancing Translational Sciences PAR-24-133
Development of a modular customizable screening platform for chimeric antigenreceptor optimization
Recipient
SOLLUS THERAPEUTICS, INC.
Award Amount
$322,576.00
Ceiling
$322,576.00
Awarded
June 16, 2026
Identifier
PAR-24-133
Award to develop a high-throughput screening platform for optimizing chimeric antigen receptor designs, funded by NCATS with a total award amount of $322,576 for fiscal year 2026.
Description
The project aims to develop a high-throughput screening platform to optimize chimeric antigen receptor (CAR) designs, focusing on reducing tonic signaling, increasing antigen sensitivity, and reducing antigen loss. The project involves developing computational models to predict optimal CAR designs based on empirical screening data.